** Elanco Animal Health's ELAN.N shares rise 8.83% to $10.35 premarket
** Company, which makes drugs for animals, reports Q1 revenue of $1.19 billion vs est $1.17 billion - LSEG
** Raises annual forecast to be between $4.51 billion and$4.58 billion vs prior expectation of $4.45 billion to $4.51 billion
** Elanco says its outlook incorporates current estimate for tariff net impact between $16 million and $20 million to adjusted core profit
** Company's updated tariff exposure appears manageable, which was a concern heading into the print, says brokerage Leerink
** Elanco posts Q1 adjusted profit of 37 cents/shr vs est 31 cents/shr
** As of last close, stock down 22%
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.